1Usarov Z.O., 2Abdukayumov A.M., 3Rikhsiev A.Z.,4Akhmedov J.A., 5Sherov O.O.
To date, one of the promising directions in the development of modern oncology is radionuclide therapy using targeted radiopharmaceuticals, that is, targeted effects on tumor tissues. For the synthesis of such targeted radiopharmaceuticals is suitable the radionuclide 177Lu with high specific activity. Currently, in world practice, the lutetium-177 radionuclide with a high specific activity is obtained by irradiating ytterbium targets enriched (with an enrichment degree >96%) in the stable isotope of ytterbium-176. Due to the high cost of highly enriched stable isotopes, their availability is not always possible. In this regard, the importance of developing a technology for the regeneration of 176Yb from spent irradiated targets with a high technological yield is promising. This work is devoted to the development of a technology for the regeneration of grams amounts of ytterbium enriched in the 176Yb isotope in the form of chloride from spent irradiated 176Yb samples with a high radiochemical yield, while ensuring high chemical purity.
https://doi.org/10.62226/ijarst20232267
PAGES : 897-899 | 56 VIEWS | 48 DOWNLOADS
1Usarov Z.O., 2Abdukayumov A.M., 3Rikhsiev A.Z.,4Akhmedov J.A., 5Sherov O.O. | Recovery of Ytterbium Enriched by Ytterbium-176 from Spent Irradiated Samples of Ytterbium-176 | DOI : https://doi.org/10.62226/ijarst20232267
| Journal Frequency: | ISSN 2320-1126, Monthly | |
| Paper Submission: | Throughout the month | |
| Acceptance Notification: | Within 6 days | |
| Subject Areas: | Engineering, Science & Technology | |
| Publishing Model: | Open Access | |
| Publication Fee: | USD 60 USD 50 | |
| Publication Impact Factor: | 6.76 | |
| Certificate Delivery: | Digital |